Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial

Phase 4

Terminated

• Conditions: Partial Seizures
• Interventions: Drug: Pregabalin

• Registration Number: NCT00407797
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration, BID) to existing standard AED (Antiepileptic drugs).

Detailed Description

This study was terminated on 17 March 2009 due to delayed enrollment. The decision to terminate the trial was not based on any safety concerns, but rather on timelines and the difficulty in enrolling patients in this open label, single group study.

Study Timeline

• Study First Submitted: 2006-12-01
• Study First Submitted QC: 2006-12-01
• Study First Posted: 2006-12-05
• Study Start: 2007-03
• Primary Completion: 2009-08
• Study Completion: 2009-08
• Results First Submitted: 2010-08-12
• Results First Submitted QC: 2010-08-12
• Results First Posted: 2010-09-09
• Status Verified: 2011-02
• Last Update Submitted: 2021-01-21
• Last Update Posted: 2021-01-25

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 136

Inclusion Criteria

• Male or Female who are diagnosed of partial seizure (simple partial, complex partial, partial seizure secondarily generalized) as defined in the international league of epilepsy classification of seizure.

Exclusion Criteria

• Patients having a treatable cause of seizure, currently receiving vigabatrin, having a progressive neurological or systemic disorder.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pregabalin	Pregabalin	-

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline in 28 Day Partial Seizure Rate During Treatment Observation Phase	Week 9 to Week 21 or End of Treatment (early termination)	28-day seizure rate (at observation period \[obs\]) = \[(number of seizures obs ) divided by (duration of period based on observed last dosing date and Visit 3 \[Week 9\] date)\] \* 28. Percent change = \[(28-day seizure rate obs minus 28-day seizure rate at baseline \[b\]) divided by 28-day seizure rate b\] \* 100. Negative values indicate a decrease in seizure frequency and positive values reflect an increase in seizure frequency.

Secondary Outcome Measures

Name	Time	Method
Response Ratio (RR)	Week 9 to Week 21 or End of Treatment (early termination)	Response ratio (RR) = comparison between baseline 28-seizure frequency with the 12 week observation phase. RR = \[(28-day seizure rate in observation period \[obs\] minus 28-day seizure rate at baseline \[b\] ) divided by (28-day seizure rate obs plus 28-day seizure rate b)\] \* 100. Range: -100 to 100; negative values for the RR indicate reductions in seizures.
Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS): Optimal Sleep Subscale	Week 21, LOCF	Optimal Sleep subscale of the MOS subject rated questionnaire to assess sleep quality and quantity. Optimal Sleep (1 of 7 subscales) was derived from sleep quantity: average hours of sleep each night during the past week. Number of subjects with response: YES=1 (optimal sleep: quantity of sleep was 7 or 8 hours per night) or No= 0 (no optimal sleep). Negative value indicates a decrease in attribute; positive value indicates an increase in attribute. Change = (MOS score at observation period minus MOS score at baseline \[b\]) divided by MOS score b.
Percent Change From Baseline in 28-Day Partial Seizure Frequency at Week 21	Week 21 or End of Treatment (early termination)	Percent change from Baseline = \[(28-day seizure rate at 21 weeks minus 28-day seizure rate at baseline \[b\]) divided by (28-day seizure rate b) \* 100. Negative values indicate a decrease in seizure frequency, positive values reflect an increase in seizure frequency.
Percent Change From Baseline in Seizure Frequency in Participants Who Had <=6 Seizures and >6 Seizures During the Baseline Period	Week 9 to Week 21 or End of Treatment (early termination)	Negative values indicate a decrease in seizure frequency; positive values reflect an increase in seizure frequency.
Percent of Seizure- Free Participants During the Treatment Observation Period	Week 9 to Week 21 or Early Termination (end of treatment)	Seizure-free = no seizures during observation period (100 percent reduction in seizures from baseline).
Percent of Seizure Free Participants During the Last 4 Weeks of the Treatment Observation Period	Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)	Seizure-free = no seizures during last 4 weeks of observation period (100 percent reduction in seizures from baseline).
Percent of Participants With >=50% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period	Week 17 to Week 21 (or Last 4 Weeks of Treatment after Week 9)
Percent of Participants With >=75% Reduction in Seizure Frequency (28-day Seizure Rate) Between Baseline and Final 4 Weeks of the Treatment Observation Period	Week 17 through Week 21 (or Last 4 Weeks of Treatment after Week 9)
Treatment Satisfaction: Patient General Impression to Change (PGIC)	Week 21, LOCF	Patient General Impression to Change (PGIC): participant rated instrument to measure participant's change in overall status since beginning study medication on a 7-point scale; range: 1 (very much improved) to 7 (very much worse). Not done = participant did not complete the PGIC.
Change From Baseline in Sleep Interference: Medical Outcome Sleep Scale (MOS)	Week 21, LOCF	Participant rated questionnaire to assess sleep quality and quantity; 9-item overall sleep problems index and 7 subscales. Sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy subscale scores (s) rated 1 (all the time) to 6 (none of the time); transformed s; total range (r): 0 to 100; higher s = greater intensity of attribute; negative values (v) = reduction from baseline (b), positive v = increase from b. Sleep Quantity score r: 0-24 hours. Higher s = greater quantity of sleep. Change = (MOS score at observation period minus MOS score at b) divided by MOS score b.
Change From Baseline in Hospital Anxiety and Depression Scale (HADS)	Week 21, LOCF	Participant rated questionnaire with 2 subscales: HADS-A assesses generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D: state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale has 7 items; range: 0 (no anxiety or depression) to 3 (severe anxiety or depression). Total score 0 to 21 for each subscale; higher score = greater severity of symptoms. Negative value = reduction from baseline (b), positive value = increase from b. Change = (HADS score at observation period minus HADS score at b) divided by HADS score b.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇲🇽 Estado de México, Mexico